Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)

Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) has developed a novel stem cell expression system for producing functional G-Protein Coupled Receptors (GPCRs), important for cancer research.

GPCRs play a significant role in cancer tumorigenesis and represent over 30% of the therapeutic drug market, valued at nearly $3.5 billion in 2022, with an annual growth rate of 5% through 2030.

The company has filed intellectual property protection for its proprietary GPCR expression platform, which is expected to create significant partnering opportunities in drug discovery and development.

This platform will be combined with their High-Throughput Self-Interaction Chromatography (HSC™) technology to enhance the solubility and stability of GPCRs, addressing existing challenges in the field.

The new technology is anticipated to launch later this year or early 2025, opening up a multi-billion-dollar market opportunity.

Positive

• Development of a novel GPCR expression system enhances cancer drug research.
• GPCRs represent over 30% of the global therapeutic drug market.
• The GPCR market was valued at $3.5 billion in 2022 with a 5% annual growth rate.
• Extensive intellectual property protection filed for the new GPCR technology.
• Potential for significant partnering opportunities with drug discovery companies.
• Combination with HSC™ technology to improve GPCR solubility and stability.
• Launch expected later this year or early 2025.

Negative

• No immediate financial gain reported from the new technology.
• Potential delays in the launch could impact market entry.
• Uncertainty regarding the effectiveness and adoption of the new platform.

Insights

Biotechnology Analyst

Predictive Oncology's new GPCR expression system represents a potential breakthrough in the field of drug discovery and development. GPCRs are important for many biological processes, including cancer progression. However, a majority of these receptors remain uncharacterized, offering significant opportunities for new therapeutic targets. The company’s IP protection for this technology is a strategic move, potentially leading to lucrative partnerships with pharmaceutical firms. This could expedite the development of new cancer drugs, addressing an unmet medical need and capitalizing on a growing market valued at $3.5 billion in 2022, with a 5% annual growth prospect. The integration of this platform with their HSC™ technology further strengthens their pipeline, solving one of the main issues in GPCR research—stability and solubility of the proteins.

Financial Analyst

Predictive Oncology Inc.'s innovation in GPCR expression systems could significantly enhance the company’s market position and revenue streams. The potential to form strategic partnerships with pharmaceutical companies opens up new revenue channels and diversifies risk. Financially, this development may result in a substantial increase in research funding and collaborations, which are important for sustaining long-term growth. The projected market growth rate of 5% annually further indicates a promising financial outlook for the company. Investors should watch for upcoming announcements regarding partnerships and the eventual market launch of this technology, as these will be key indicators of the company’s financial health and market penetration.

Market Research Analyst

The introduction of the new GPCR expression system by Predictive Oncology could disrupt the lucrative GPCR drug market which is currently valued at $3.5 billion and growing. With GPCRs playing a significant role in therapeutic drugs, the company’s new technology addresses a critical gap in the market—characterization and stability of GPCR targets. This positions Predictive Oncology to capture a substantial market share and establish itself as a key player in the biotech industry. The company's emphasis on filing expansive intellectual property protection also safeguards its market position against competitors. Long-term, this could affect stock valuation positively, provided the technology meets commercial and clinical expectations.

Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development

External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annually through 2030¹

PITTSBURGH, June 11, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (GPCRs).

GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis. It is estimated that drugs targeting GPCRs represent more than 30% of the global market for therapeutic drugs, yet the number of characterized GPCR targets represent just a small fraction of the GPCR superfamily, suggesting significant potential to further target GPCRs for future drug discovery and development^2,3.    

“As a result of our sustained efforts to develop this technology, Predictive Oncology has been able to file expansive intellectual property (IP) protection for its novel GPCR expression platform,” said Dr. Larry DeLucas, SVP of Biologics for Predictive Oncology. “We believe that this technology will open significant partnering opportunities for our company, and we look forward to working with drug discovery and development companies that are targeting GPCRs to expand their portfolios and replenish their pipelines.”

Predictive Oncology plans to combine this proprietary GPCR expression system with its current High-Throughput Self-Interaction Chromatography (HSC™) protein solubilization technology to enable the rapid identification of solution conditions that maintain purified GPCRs in a soluble and stable form. The company believes this can overcome many of the difficulties seen with existing expression technologies.

“We are very pleased to introduce our new platform to potential pharma partners targeting GPCRs of interest,” stated Raymond Vennare, Chief Executive Officer of Predictive Oncology. “This technology represents a significant advancement over previous expression methodologies which, once launched later this year or in early 2025, will allow us to contribute to the advancement of new cancer therapeutics while tapping into a multi-billion-dollar annual market opportunity for GPCRs in the U.S. alone.”

About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA lab and GMP facilities. Predictive Oncology is headquartered in Pittsburgh, PA. 

Investor Relations Contact
Tim McCarthy  
LifeSci Advisors, LLC  
tim@lifesciadvisors.com

Forward-Looking Statements: 
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements. 

¹Grand View Research. https://www.grandviewresearch.com/industry-analysis/g-protein-coupled-receptors-gpcrs-market;

² Persistence Market Research: https//www.persistencemarketresearch.com/market-research/q-protein-coupled-receptors-market.asp

³ https://pubmed.ncbi.nlm.nih.gov/34194261/

FAQ

What is Predictive Oncology's new GPCR expression system?

Predictive Oncology has developed a novel stem cell expression system for producing functional and stable G-Protein Coupled Receptors (GPCRs).

Why are GPCRs important in cancer research?

GPCRs play a key role in tumorigenesis, including cancer initiation, progression, and metastasis.

What is the market value of GPCR-targeting drugs?

The GPCR market was valued at nearly $3.5 billion in 2022 and is growing at an annual rate of over 5% through 2030.

What are the potential benefits of Predictive Oncology's new technology?

The new technology could enable better solubility and stability of GPCRs, opening significant partnering opportunities and enhancing drug discovery.

When will Predictive Oncology's new GPCR platform launch?

The new GPCR platform is expected to launch later this year or early 2025.

How will Predictive Oncology protect its new GPCR technology?

The company has filed expansive intellectual property protection for its novel GPCR expression platform.

What are the risks associated with Predictive Oncology's new technology?

There are uncertainties regarding the effectiveness and adoption of the new platform, and potential delays in the launch could impact market entry.